key: cord-0980148-c4j3sxyw
authors: Karatas, Murat; Tatar, Erhan; Simsek, Cenk; Yıldırım, Ali Murat; Ari, Alpay; Zengel, Baha; Uslu, Adam
title: COVID‐19 pneumonia in kidney transplant recipients: A promising treatment algorithm in the absence of a disease‐specific drug
date: 2021-06-06
journal: J Med Virol
DOI: 10.1002/jmv.27110
sha: cc250e9071c4788669538b7ea575d61fc8daa860
doc_id: 980148
cord_uid: c4j3sxyw

There is no consensus on the management of coronavirus disease 2019 (COVID‐19) and modification of immunosuppressive therapy in kidney transplant recipients (KTRs). In this study, we examined the clinical outcome of our KTRs with COVID‐19 disease, who were treated with a broad‐spectrum anti‐inflammatory protocol. This protocol is essentially composed of intravenous immunoglobulin +/‐ tocilizumab in KTRs with severe COVID‐19 pneumonia. Among 809 KTRs, 64 patients diagnosed with COVID‐19 disease between April 2020 and February 2021, were evaluated. Twenty‐nine patients with pneumonia confirmed by chest computed tomography (CCT) were hospitalized. The treatment protocol included high‐dose intravenous methylprednisolone, favipiravir, enoxaparin, and empirical antibiotics. Patients with pneumonic involvement of more than 25% on CCT with or without respiratory failure were given a total of 2 g/kg intravenous immunoglobulin (IVIg) therapy. Nonresponders received tocilizumab, an interleukin‐6 receptor antibody. Of the 29 patients with pneumonia, 6 were treated in other hospitals. These six patients did not receive IVIg and 5 of them deceased. In our center, IVIg treatment was applied to 15 of 23 patients. Seven of them required tocilizumab. Respiratory parameters improved significantly in all but one patient after IVIg ± tocilizumab treatment. The mortality rate was 6.6% in patients who received IVIg therapy and 35.7% in those who did not (p = 0.08). The mortality rate was higher in patients who received treatment in external centers (2.2% vs. 26.3%; p = 0.0073). The treatment of KTRs with severe COVID‐19 pneumonia in organ transplant centers with significant experience yields better results. The administration of broad‐spectrum anti‐inflammatory treatment in this patient group was safe and provided excellent outcomes.

and then spread worldwide. By February 2021, the number of confirmed cases of infection was over 111 million; there have been almost 2.5 million deaths reported globally since the start of the pandemic. 1 The severe form of COVID-19 has been associated with older age and comorbidities, such as diabetes, hypertension, morbid obesity, coronary heart disease, and chronic obstructive pulmonary disease. 2 Patients with solid organ transplantation are prone to increased risk of infection and poor outcomes due to their long-term immunocompromised status and existing comorbidities. Compared with the general population, kidney transplant recipients (KTRs) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have higher rates of severe disease (44% vs. 6.1%) and mortality (24%-28% vs. 1.4%-4.3%). 3, 4 To date, there is no clear consensus on the management of COVID-19 and modification of immunosuppressive therapy in KTRs.

Also, there is no drug with proven efficacy against COVID-19. Intravenous immunoglobulin therapy (IVIg) has been tried in severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which are members of the coronavirus family, and some beneficial effects have been reported. [5] [6] [7] IVIg is a blood product containing polyclonal immunoglobulin G obtained from pooled healthy donors. 8 IVIg may regulate the immune response by blocking proinflammatory cytokines, neutralizing activated complement components, and modulating Bcell functions. 9 In this study, we examined the clinical outcome of our KTRs with COVID-19 disease, who were treated in our center or in different hospitals that do not have organ transplant units. Thus, we aimed to determine the effect of differences in decisionmaking on the course of COVID-19 that may occur between centers. Also, we examined the demographics and clinical and laboratory parameters associated with COVID-19 infection in KTRs and investigated the efficacy of IVIg in the management of COVID-19 pneumonia.

Currently, 809 KTRs are being followed at Health Sciences University Bozyaka Organ Transplantation and Research Center.

Among these, patients diagnosed as having COVID-19 between April 2020 and February 2021 were evaluated. Chest CT (CCT) images were obtained from all patients who were admitted with respiratory failure, a high respiratory rate (≥24/min.), or low oxygen saturation (SpO 2 < 93%). Respiratory failure (Rf) is defined by an arterial oxygen tension (P aO2 ) of <60 mmHg or an arterial carbon dioxide tension (P aCO2 ) of >45 mmHg or both. 10 COVID-19 disease was classified as mild, moderate, and severe according to the severity of pneumonic infiltration in CCT. The KTRs with pneumonia with or without Rf were hospitalized in COVID-19 units, and patients with the mild clinical presentation were managed as outpatients. The treatment of all patients followed in our center was administered on a consensus basis by the surgeon, nephrologist, and infectious diseases specialist in the organ transplant unit.

The patients were divided into two groups as those receiving treatment in our center or in a different center.

SARS-CoV-2 infection was detected in nasopharyngeal swabs using real-time reverse-transcription polymerase chain reaction (RT-PCR). In the event of a negative quantitative RT-PCR test result, if the patient had a clinical presentation compatible with COVID-19 infection and supported by CT images, a second nasopharyngeal swab was performed.

Routine blood tests included complete blood count, coagulation profile, kidney and liver function tests, lactate dehydrogenase, electrolytes, myocardial enzymes, serum ferritin level, C-reactive protein (CRP), D-dimer, and procalcitonin. Acute kidney injury (AKI) was defined according to the Kidney Disease: Improving Global Outcomes clinical practice guidelines. 11 In this study, our policy in the management of immunosuppression was compatible with ERA-EDTA DESCARTES expert opinion. 12 The immunosuppressive drug regimen was modified in all patients. In patients without pneumonia, MPA, AZA, or mTORi was discontinued and the immunosuppression protocol was arranged as steroid (3 mg/kg/day) and CNI. Also, considering the immunological risk of each patient, a reduction of 30% to 50% was made in CNI drug dosages for the first 5 days of Following this treatment, patients who did not achieve an arterial oxygen tension (P aO2 ) of ≥60 mmHg and/or carbon dioxide tension (P aCO2 ) of less than 45 mmHg were accepted as nonresponders. These patients received tocilizumab (Actemra/ RoActemra; 400 mg/20 ml; F. Hoffmann-La Roche Ltd.), an interleukin (IL)−6 receptor antibody, with a total dose of 800 mg.

The treatment flowchart of patients with COVID-19 pneumonia is depicted in Figure 1 . Our treatment flowchart was sent to all external centers where our patients were treated, and the same treatment practices were recommended as much as possible.

This study was approved by the hospital's ethics committee for clinical trials (Decision no.: 2021/15). All patients signed written informed consent before the administration of the treatment.

All statistical analyses were performed using SPSS version 16.0.

p values of less than 0.05 were considered to be statistically significant. For normally distributed data, we compared means using Student's t test, and when data were not normally distributed, we used the Mann-Whitney U test. Fisher's exact test was used for the comparison of proportions. The average hospital stay was 12 ± 5 (range, 7-28) days. The clinical findings detected in the patients at the time of admission were cough (77%), high fever (50.4%), shortness of breath (30%), loss of taste and smell (26.4%), and diarrhea (19.2%). Thirty-five patients without pneumonia (Group A) were compared with 29 patients with pneumonia (Group B). (Table 1) The demographic data of both groups were similar, and no difference was observed between comorbid diseases and the applied immunosuppressive treatment regimens.

There was also no difference between Groups A and B in terms of time after transplantation (92.9 ± 77.6 vs. 88.5 ± 67.4 months respectively, p = 0.82). However, compared to patients with mild to moderate and severe pneumonia, patients without pneumonia had statistically significantly lower posttransplant DGF rate (14% vs. 47% and 75%, p = 0.001), and higher basal glomerular filtration rate (GFR) value (62 ± 18 vs. 48 ± 21 and 42 ± 24 ml/min/1.72 m 2 , p = 0.008). As a result, it was determined that the better the allograft function, the lower the risk of pneumonia. center. Among these, the percentage of pneumonic infiltration in CCT was 5%-25% in two, 26%-50% in five, 51%-75% in seven, and greater than 75% in one patient. After IVIg treatment, tocilizumab was added to the treatment in seven patients due to the lack of the expected improvement in acute respiratory failure. In these seven patients, there was a decrease in mean CRP (176.5 ± 127.8 vs.

90.0 ± 68.2 mg/L, p = 0.12) and procalcitonin values (20.1 ± 1.9 vs.

16.5 ± 1.0, p = 0.9) after IVIg therapy. However, an arterial oxygen tension of 60 mmHg and above could not be achieved in any patient.

However, following tocilizumab treatment, respiratory parameters (SpO 2 , PaO 2 ) improved significantly in all but one patient. Twentynine patients with pneumonia were examined in two groups as those who received IVIg treatment and those who did not. Among the groups, there was no significant difference in the demographic characteristics, renal function parameters, and acute-phase reactants at the time of admission ( IVIg treatment, pneumonic infiltration was completely resolved in 10 of them. Also, pneumonic involvement regressed to the level of 5%-25% in two and less than 5% in two patients. The patient, who had greater than 75% involvement of the lung parenchyma at the time of admission, deceased during the treatment process.

We observed no thromboembolic complications in any patient during and after treatment.

Although not statistically significant, the mortality rate was lower in patients who received IVIg. When the relationship between survival and comorbidity was examined, the mortality rate in diabetic, hypertensive, and obese patients compared to transplant recipients without any additional disease was (7% vs. 10%, p = 0.75), 

In this study, which was conducted on COVID-19 pneumonia and its treatment in KTRs, we focused on two main points. One was on the assumption that the treatment and care given in this patient group by experienced organ transplant centers would yield much better results. Indeed, supporting our hypothesis, among the 29 KTRs with pneumonia, only one of the 23 patients treated at our center and five of the six patients managed in external centers died (4.3% vs. 83.3%, p < 0.001). This result emphasizes the importance of clinical experience and adherence to the treatment protocol in the management of severe infections in KTRs.

The second point we investigated was whether IVIg treatment would provide an additional benefit and improve survival parameters in this patient group. In our previous case report, we suggested that IVIg could be an important treatment option in a kidney transplant patient who presented with severe COVID-19 pneumonia. 13 In KTRs, IVIg has been used for the prevention and treatment of antibody-mediated rejection, as an adjunct therapy for the human BK polyomavirus-associated nephropathy, and posttransplant infectious complications, including cytomegalovirus and parvovirus B19. [14] [15] [16] Although the clinical results are inconclusive, IVIg has been used in the management of more lethal varieties of coronaviruses as SARS and MERS in the general population. 14 IVIg exerts an antiinflammatory effect by binding to proinflammatory cytokines or variable anti-idiotypic antibodies. These effects may account for its clinical benefit. 17 We were only able to administer IVIg treatment to 15 In our treatment protocol, RTRs with SARS-CoV-2 infection initially received high-dose IVIg and corticosteroid treatments, which have the potential for cytokine inhibition. 8 Those who did not achieve PaO 2 ≥ 60 mmHg after this treatment received tocilizumab.

These nonspecific immune modulators applied before may have improved the therapeutic results expected from tocilizumab.

In a recent report, including 80 KTRs, tocilizumab efficiently reduced CRP levels and this decrease positively correlated with survival. 25 In another small-scale, single-center study, including 10

KT patients with severe COVID-19, a single dose of tocilizumab (400-600 mg) decreased CRP levels, improved the clinical course, reduced oxygen requirement, and provided hospital discharge in seven patients. 26 In our study, we used tocilizumab in seven patients whose PaO 2 levels were between 50 and 54 mmHg after IVIg treatment. Following tocilizumab, PaO 2 increased above 60 mmHg in all cases. The respiratory parameters improved and all but one patient were discharged with recovery.

All patients with pneumonia received corticosteroid treatment with varying doses (280-910 mg/total dose). In these patients, the KARATAS ET AL. | 7 discontinuation of antiproliferative agents and calcineurin inhibitors mandated us to administer high-dose corticosteroids, which was the only option for maintenance immunosuppression. However, we do not consider this as a confounding factor on the efficacy of IVIg and tocilizumab treatments. Our study had several limitations. First of all, it was a single-center, retrospective cohort study, and had no comparative group. Also, the sample size was small, restricting the power of the study. However, it is interesting because it is the first study in which a broad-spectrum anti-inflammatory protocol was used for COVID-19 pneumonia in KTRs.

As observed in this study, the treatment of KTRs with severe COVID-19 pneumonia in organ transplant centers with significant experience in issues, such as infection treatment, immunosuppression modification, and treatment complications, yields better results. The administration of broad-spectrum antiinflammatory treatment in this patient group was safe and provided excellent outcomes.

Coronavirus disease (COVID-19) situation report

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19 in solid organ transplant recipients: initial report from the US epicenter

Covid-19 and kidney transplantation

Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients

Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection

SARS: systemic review of treatment effects

Pharmaco-immunomodulatory therapy in COVID-19

Immunoglobulins in the treatment of COVID-19 infection: proceed with caution!

Respiratory failure

Clinical practice guideline for acute kidney injury

How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion

Intravenous immunoglobulin and favipiravir treatment for a kidney transplant patient with severe Covid-19 pneumonia

Intravenous immunoglobulin in kidney transplantation

Polyomavirus in solid organ transplantation

Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients

High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects

Early description of coronavirus 2019 disease in kidney transplant recipients in New York

COVID-19 infection in kidney transplant recipients

A systematic review of COVID-19 and kidney transplantation

Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: A multicenter retrospective cohort study

Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19

Efficacy of tocilizumab in patients hospitalized with COVID-19

Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A Randomized Clinical

Spanish Society of Nephrology COVID-19 Group. Use of tocilizumab in kidney transplant recipients with COVID-19

Tocilizumab use in kidney transplant patients with COVID-19

Native-speaker English editing is carried out by David F. Chapman BSc (Hons) (Certificate No: 2021-0315-03). The authors received no financial support for the research, authorship, and/or publication of this article.

The authors declare that there are no conflicts of interest with respect to the research, authorship, and/or publication of this article.

Informed consent was obtained from all individual participants included in the study.

Karatas M, and Tatar E equally contributed to the conception and design of the study. Karatas M, Yıldırım AM, and Uslu A contributed to the assembly, analysis, and interpretation of data. Tatar E, Zengel B, Ari A performed the statistical analysis. Simsek C, Karatas M, and Ari A participated in the drafting of the article. Tatar E, and Uslu A